Author

J. M. Pascal

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Biochemistry· 5 Cell Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 6 Assay:proteomics· 3 Approach:biophysical modeling· 2 Research Focus:drug response / drug discovery· 2 Research Focus:host-pathogen & immune response· 2 Organism:human· 2 Organism:mouse· 2 Research Focus:protein folding & dynamics· 2

Frequent Co-Authors

M.-F. Langelier· 4 shared B. E. Black· 2 shared R. Billur· 2 shared A. Leung· 1 shared A. Rasti· 1 shared A. Sverzhinsky· 1 shared A. Throup· 1 shared B. D. G. Page· 1 shared

Activity by Year

2021-2024 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 19 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersBiochemistry

M.-F. Langelier

Mutual co-authors in cluster

Author profile →

6 papers

Recent·Most cited

A PARP2-specific active site alpha-helix melts to permit DNA damage-induced enzymatic activation

E. S. Smith-Pillet, R. Billur, M.-F. Langelier, T. T. Talele, J. M. Pascal, B. E. Black

This study identifies structural differences in PARP1 and PARP2 activation mechanisms, showing that PARP2 requires an active site alpha-helix to be unfolded for DNA damage-induced activation, unlike PARP1.

bioRxiv · May 20, 2024 · PreprintBiochemistry

Clinical PARP inhibitors allosterically induce PARP2 retention on DNA

M.-F. Langelier, X. Lin, S. Zha, J. M. Pascal

This study shows clinical PARP inhibitors can allosterically retain PARP2 on DNA breaks, differing from their effect on PARP1, with implications for PARPi toxicity and design.

bioRxiv · Nov 8, 2022Biochemistry

Coupling cellular drug-target engagement to downstream pharmacology with CeTEAM

N. C. K. Valerie, K. Sanjiv, O. Mortusewicz, S. M. Zhang, S. Alam, M. J. Pires, H. Stigsdotter, A. Rasti, M.-F. Langelier, D. Rehling, A. Throup, M. Desroses, J. Onireti, P. Wakchaure, I. Almlof, , M. Altun

CeTEAM evaluates drug-target interactions and phenotypic responses using biosensors, revealing how drug binding affects cellular activities and metabolism.

bioRxiv · Sep 19, 2022Biochemistry

Crystal structures and functional analysis of the ZnF5-WWE1-WWE2 region of PARP13/ZAP define a new mode of engaging poly(ADP-ribose)

J. R. A. Kuttiyatveetil, H. Soufari, M. Dasovich, I. R. Uribe, S.-J. Cheng, A. Leung, J. M. Pascal

The paper presents crystal structures of the ZnF5-WWE1-WWE2 region of PARP13 and shows it binds poly(ADP-ribose) through WWE2, revealing a new mode of recognition.

bioRxiv · Dec 15, 2021 · PreprintBiochemistry

Tankyrase interacts with the allosteric site of glucokinase and inhibits its glucose-sensing function in the beta cell

N.-W. Chi, T. Eisemann, T.-Y. J. Yeh, S. Roy, T. J. Chi, S. H. Lu, J. M. Pascal, O. Osborn

This study identifies tankyrase (TNKS) as a physiological inhibitor of glucokinase (GCK) in pancreatic beta cells by trapping it in an inactive conformation.

bioRxiv · Aug 8, 2021 · PreprintCell Biology

HPF1 dynamically controls the PARP1/2 balance between initiating and elongating ADPribose modifications

M.-F. Langelier, R. Billur, A. Sverzhinsky, B. E. Black, J. M. Pascal

This study shows HPF1 regulates PARP1/2 to balance initiation and elongation of ADP-ribose modifications, ensuring efficient serine modification during DNA damage response.

bioRxiv · May 19, 2021Biochemistry